Eduardo Antonio Ferraz Coelho

List of Publications by Citations

142 papers	2,641 citations	27 h-index	42 g-index
147 ext. papers	3,092 ext. citations	3.5 avg, IF	4.5 L-index

#	Paper	IF	Citations
142	Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. *Infection and Immunity*, **2003**, 71, 3988-94	3.7	183
141	Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. *Vaccine*, **2008**, 26, 5888-95	4.1	132
140	Identification of proteins in promastigote and amastigote-like Leishmania using an immunoproteomic approach. *PLoS Neglected Tropical Diseases*, **2012**, 6, e1430	4.8	77
139	Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives. *Current Opinion in Microbiology*, **2012**, 15, 476-85	7.9	63
138	Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections. *Microbes and Infection*, **2007**, 9, 1070-7	9.3	63
137	Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2148	4.8	59
136	Leishmanicidal activity of the Agaricus blazei Murill in different Leishmania species. *Parasitology International*, **2011**, 60, 357-63	2.1	58
135	New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment. *Revista Da Sociedade Brasileira De Medicina Tropical*, **2015**, 48, 235-42	1.5	56
134	Field randomized trial to evaluate the efficacy of the Leish-Tec vaccine against canine visceral leishmaniasis in an endemic area of Brazil. *Vaccine*, **2016**, 34, 2233-9	4.1	50
133	Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge. *Parasitology Research*, **2005**, 98, 67-74	2.4	50
132	Proteins Selected in Leishmania (Viannia) braziliensis by an Immunoproteomic Approach with Potential Serodiagnosis Applications for Tegumentary Leishmaniasis. *Vaccine Journal*, **2015**, 22, 1187-96		46
131	Evaluation of parasitological and immunological parameters of Leishmania chagasi infection in BALB/c mice using different doses and routes of inoculation of parasites. *Parasitology Research*, **2012**, 110, 1277-85	2.4	45
130	Novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system. *International Journal of Nanomedicine*, **2014**, 9, 877-90	7.3	39
129	Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge. *Microbes and Infection*, **2010**, 12, 967-77	9.3	38
128	Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis. *Vaccine*, **2013**, 31, 1312-9	4.1	37
127	Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis. *Revista Da Sociedade Brasileira De Medicina Tropical*, **2016**, 49, 398-407	1.5	37
126	Antileishmanial activity and cytotoxicity of Brazilian plants. *Experimental Parasitology*, **2014**, 143, 60-8	2.1	32

125	A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis. *Parasites and Vectors*, **2015**, 8, 363	4	31
124	An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis. *Veterinary Parasitology*, **2016**, 217, 81-8	2.8	31
123	Poloxamer 407 (Pluronic( ) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis. *Experimental Parasitology*, **2016**, 169, 34-42	2.1	30
122	A recombinant chimeric protein composed of human and mice-specific CD4 and CD8 T-cell epitopes protects against visceral leishmaniasis. *Parasite Immunology*, **2017**, 39, e12359	2.2	30
121	Prophylactic properties of a Leishmania-specific hypothetical protein in a murine model of visceral leishmaniasis. *Parasite Immunology*, **2015**, 37, 646-56	2.2	30
120	An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis. *International Journal of Nanomedicine*, **2014**, 9, 5341-53	7.3	30
119	Specific serodiagnosis of canine visceral leishmaniasis using Leishmania species ribosomal protein extracts. *Vaccine Journal*, **2009**, 16, 1774-80		30
118	Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis. *Parasites and Vectors*, **2014**, 7, 3	4	29
117	Treatment of murine visceral leishmaniasis using an 8-hydroxyquinoline-containing polymeric micelle system. *Parasitology International*, **2016**, 65, 728-736	2.1	29
116	Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis. *PLoS ONE*, **2014**, 9, e110014	3.7	28
115	Antileishmanial Activity, Cytotoxicity and Mechanism of Action of Clioquinol Against Leishmania infantum and Leishmania amazonensis Species. *Basic and Clinical Pharmacology and Toxicology*, **2018**, 123, 236-246	3.1	27
114	Identification of immune biomarkers related to disease progression and treatment efficacy in human visceral leishmaniasis. *Immunobiology*, **2018**, 223, 303-309	3.4	27
113	Mapping B-cell epitopes for the peroxidoxin of Leishmania (Viannia) braziliensis and its potential for the clinical diagnosis of tegumentary and visceral leishmaniasis. *PLoS ONE*, **2014**, 9, e99216	3.7	27
112	Recombinant prohibitin protein of Leishmania infantum acts as a vaccine candidate and diagnostic marker against visceral leishmaniasis. *Cellular Immunology*, **2018**, 323, 59-69	4.4	27
111	Antileishmanial activity and evaluation of the mechanism of action of strychnobiflavone flavonoid isolated from Strychnos pseudoquina against Leishmania infantum. *Parasitology Research*, **2015**, 114, 4625-35	2.4	25
110	Identification of differentially expressed proteins from Leishmania amazonensis associated with the loss of virulence of the parasites. *PLoS Neglected Tropical Diseases*, **2014**, 8, e2764	4.8	25
109	A new Leishmania-specific hypothetical protein and its non-described specific B cell conformational epitope applied in the serodiagnosis of canine visceral leishmaniasis. *Parasitology Research*, **2016**, 115, 1649-58	2.4	24
108	Evaluation of two recombinant Leishmania proteins identified by an immunoproteomic approach as tools for the serodiagnosis of canine visceral and human tegumentary leishmaniasis. *Veterinary Parasitology*, **2016**, 215, 63-71	2.8	24

107	Mycobacterium hsp65 DNA entrapped into TDM-loaded PLGA microspheres induces protection in mice against Leishmania (Leishmania) major infection. *Parasitology Research*, **2006**, 98, 568-75	2.4	24
106	Antileishmanial activity and mechanism of action from a purified fraction of Zingiber officinalis Roscoe against Leishmania amazonensis. *Experimental Parasitology*, **2016**, 166, 21-8	2.1	24
105	Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis. *Experimental Parasitology*, **2018**, 186, 24-35	2.1	23
104	Sensitive and specific serodiagnosis of Leishmania infantum infection in dogs by using peptides selected from hypothetical proteins identified by an immunoproteomic approach. *Vaccine Journal*, **2013**, 20, 835-41		23
103	Prophylactic or therapeutic administration of Agaricus blazei Murill is effective in treatment of murine visceral leishmaniasis. *Experimental Parasitology*, **2012**, 132, 228-36	2.1	22
102	A vaccine combining two Leishmania braziliensis proteins offers heterologous protection against Leishmania infantum infection. *Molecular Immunology*, **2016**, 76, 70-9	4.3	22
101	Leishmania infantum mimotopes and a phage-ELISA assay as tools for a sensitive and specific serodiagnosis of human visceral leishmaniasis. *Diagnostic Microbiology and Infectious Disease*, **2017**, 87, 219-225	2.9	21
100	Strychnos pseudoquina and Its Purified Compounds Present an Effective In Vitro Antileishmanial Activity. *Evidence-based Complementary and Alternative Medicine*, **2013**, 2013, 304354	2.3	21
99	An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis. *Parasitology Research*, **2016**, 115, 4083-4095	2.4	21
98	In vivo antileishmanial efficacy of a naphthoquinone derivate incorporated into a Pluronic F127-based polymeric micelle system against Leishmania amazonensis infection. *Biomedicine and Pharmacotherapy*, **2019**, 109, 779-787	7.5	21
97	Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production. *Memorias Do Instituto Oswaldo Cruz*, **2010**, 105, 818-22	2.6	20
96	Vaccination with a CD4 and CD8 T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis. *Translational Research*, **2018**, 200, 18-34	11	20
95	Serological diagnosis and prognostic of tegumentary and visceral leishmaniasis using a conserved Leishmania hypothetical protein. *Parasitology International*, **2018**, 67, 344-350	2.1	19
94	Phage-fused epitopes from Leishmania infantum used as immunogenic vaccines confer partial protection against Leishmania amazonensis infection. *Parasitology*, **2015**, 142, 1335-47	2.7	19
93	Subtractive phage display selection from canine visceral leishmaniasis identifies novel epitopes that mimic Leishmania infantum antigens with potential serodiagnosis applications. *Vaccine Journal* , **2014**, 21, 96-106		19
92	Antigenicity of phage clones and their synthetic peptides for the serodiagnosis of canine and human visceral leishmaniasis. *Microbial Pathogenesis*, **2017**, 110, 14-22	3.8	18
91	Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis. *Experimental Parasitology* , **2015**, 153, 180-90	2.1	18
90	A new Leishmania-specific hypothetical protein, LiHyT, used as a vaccine antigen against visceral leishmaniasis. *Acta Tropica*, **2016**, 154, 73-81	3.2	18

89	Epitope mapping of the HSP83.1 protein of Leishmania braziliensis discloses novel targets for immunodiagnosis of tegumentary and visceral clinical forms of leishmaniasis. *Vaccine Journal*, **2014**, 21, 949-59		18
88	Therapeutic efficacy induced by the oral administration of Agaricus blazei Murill against Leishmania amazonensis. *Parasitology Research*, **2012**, 111, 1807-16	2.4	18
87	An ELISA immunoassay employing a conserved Leishmania hypothetical protein for the serodiagnosis of visceral and tegumentary leishmaniasis in dogs and humans. *Cellular Immunology*, **2017**, 318, 42-48	4.4	17
86	Antileishmanial activity of compounds produced by endophytic fungi derived from medicinal plant Vernonia polyanthes and their potential as source of bioactive substances. *World Journal of Microbiology and Biotechnology*, **2015**, 31, 1793-800	4.4	17
85	Antileishmanial activity of a naphthoquinone derivate against promastigote and amastigote stages of Leishmania infantum and Leishmania amazonensis and its mechanism of action against L. amazonensis species. *Parasitology Research*, **2018**, 117, 391-403	2.4	17
84	A Leishmania hypothetical protein-containing liposome-based formulation is highly immunogenic and induces protection against visceral leishmaniasis. *Cytokine*, **2018**, 111, 131-139	4	17
83	Theranostic applications of phage display to control leishmaniasis: selection of biomarkers for serodiagnostics, vaccination, and immunotherapy. *Revista Da Sociedade Brasileira De Medicina Tropical*, **2015**, 48, 370-9	1.5	17
82	A recombinant fusion protein displaying murine and human MHC class I- and II-specific epitopes protects against Leishmania amazonensis infection. *Cellular Immunology*, **2017**, 313, 32-42	4.4	16
81	Antileishmanial activity of standardized fractions of Stryphnodendron obovatum (Barbatimão) extract and constituent compounds. *Journal of Ethnopharmacology*, **2015**, 165, 238-42	5	16
80	New serological tools for improved diagnosis of human tegumentary leishmaniasis. *Journal of Immunological Methods*, **2016**, 434, 39-45	2.5	16
79	A Pluronic® F127-based polymeric micelle system containing an antileishmanial molecule is immunotherapeutic and effective in the treatment against Leishmania amazonensis infection. *Parasitology International*, **2019**, 68, 63-72	2.1	15
78	Evaluation of a hypothetical protein for serodiagnosis and as a potential marker for post-treatment serological evaluation of tegumentary leishmaniasis patients. *Parasitology Research*, **2017**, 116, 1197-1206	2.4	14
77	Selection strategy of phage-displayed immunogens based on an in vitro evaluation of the Th1 response of PBMCs and their potential use as a vaccine against Leishmania infantum infection. *Parasites and Vectors*, **2017**, 10, 617	4	14
76	Potential application of small myristoylated protein-3 evaluated as recombinant antigen and a synthetic peptide containing its linear B-cell epitope for the serodiagnosis of canine visceral and human tegumentary leishmaniasis. *Immunobiology*, **2019**, 224, 163-171	3.4	14
75	An in silico functional annotation and screening of potential drug targets derived from Leishmania spp. hypothetical proteins identified by immunoproteomics. *Experimental Parasitology*, **2017**, 176, 66-74	2.1	13
74	A clioquinol-containing Pluronic F127 polymeric micelle system is effective in the treatment of visceral leishmaniasis in a murine model. *Parasite*, **2020**, 27, 29	3	13
73	Small Myristoylated Protein-3, Identified as a Potential Virulence Factor in Leishmania amazonensis, Proves to be a Protective Antigen against Visceral Leishmaniasis. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	13
72	Antigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral Leishmaniasis. *PLoS ONE*, **2015**, 10, e0137683	3.7	13

71	A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against infection. *Npj Vaccines*, **2020**, 5, 75	9.5	13
70	New antigens for the serological diagnosis of human visceral leishmaniasis identified by immunogenomic screening. *PLoS ONE*, **2018**, 13, e0209599	3.7	13
69	Annexin A1 Is Involved in the Resolution of Inflammatory Responses during Infection. *Journal of Immunology*, **2017**, 198, 3227-3236	5.3	12
68	Screening diagnostic candidates from proteins for human visceral leishmaniasis using an immunoproteomics approach. *Parasitology*, **2019**, 146, 1467-1476	2.7	12
67	Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice. *PLoS Neglected Tropical Diseases*, **2015**, 9, e0003751	4.8	12
66	Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species. *Acta Tropica*, **2016**, 158, 220-230	3.2	12
65	A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from Leishmania braziliensis cross-protection against Leishmania amazonensis infection. *Immunobiology*, **2017**, 222, 251-260	3.4	12
64	Probing the efficacy of a heterologous Leishmania/L. Viannia braziliensis recombinant enolase as a candidate vaccine to restrict the development of L. infantum in BALB/c mice. *Acta Tropica*, **2017**, 171, 8-16	3.2	11
63	A conserved Leishmania hypothetical protein evaluated for the serodiagnosis of canine and human visceral and tegumentary leishmaniasis, as well as a serological marker for the posttreatment patient follow-up. *Diagnostic Microbiology and Infectious Disease*, **2018**, 92, 196-203	2.9	11
62	A rapid diagnostic test for human Visceral Leishmaniasis using novel antigens in a Laser Direct-Write Lateral Flow Device. *Emerging Microbes and Infections*, **2019**, 8, 1178-1185	18.9	11
61	Evaluation of a prototype flow cytometry test for serodiagnosis of canine visceral leishmaniasis. *Vaccine Journal*, **2013**, 20, 1792-8		11
60	Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infection. *Molecular Immunology*, **2019**, 106, 108-118	4.3	11
59	Recombinant small glutamine-rich tetratricopeptide repeat-containing protein of Leishmania infantum: Potential vaccine and diagnostic application against visceral leishmaniasis. *Molecular Immunology*, **2017**, 91, 272-281	4.3	10
58	Immunogenomic screening approach to identify new antigens for the serological diagnosis of chronic ChagasVdisease. *Applied Microbiology and Biotechnology*, **2018**, 102, 6069-6080	5.7	10
57	High-through identification of T cell-specific phage-exposed mimotopes using PBMCs from tegumentary leishmaniasis patients and their use as vaccine candidates against Leishmania amazonensis infection. *Parasitology*, **2019**, 146, 322-332	2.7	10
56	Antigenicity, immunogenicity and protective efficacy of a conserved Leishmania hypothetical protein against visceral leishmaniasis. *Parasitology*, **2018**, 145, 740-751	2.7	10
55	Diagnostic application of recombinant Leishmania proteins and evaluation of their in vitro immunogenicity after stimulation of immune cells collected from tegumentary leishmaniasis patients and healthy individuals. *Cellular Immunology*, **2018**, 334, 61-69	4.4	10
54	A biomarker for tegumentary and visceral leishmaniasis based on a recombinant Leishmania hypothetical protein. *Immunobiology*, **2019**, 224, 477-484	3.4	9

53	Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis. *Experimental Parasitology*, **2019**, 199, 30-37	2.1	9
52	Immunodiagnosis of human and canine visceral leishmaniasis using recombinant Leishmania infantum Prohibitin protein and a synthetic peptide containing its conformational B-cell epitope. *Journal of Immunological Methods*, **2019**, 474, 112641	2.5	9
51	Immunization with the HisAK70 DNA Vaccine Induces Resistance against Infection in BALB/c Mice. *Vaccines*, **2019**, 7,	5.3	9
50	Diagnostic evaluation of the amastin protein from Leishmania infantum in canine and human visceral leishmaniasis and immunogenicity in human cells derived from patients and healthy controls. *Diagnostic Microbiology and Infectious Disease*, **2019**, 95, 134-143	2.9	8
49	Tubulin Identified by Reverse Engineering Technology through Phage Display Applied as Theranostic Marker for Human Visceral Leishmaniasis. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	8
48	Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis. *Vaccines*, **2020**, 8,	5.3	8
47	Recombinant Leishmania eukaryotic elongation factor-1 beta protein: A potential diagnostic antigen to detect tegumentary and visceral leishmaniasis in dogs and humans. *Microbial Pathogenesis*, **2019**, 137, 103783	3.8	8
46	Canine visceral leishmaniasis: Detection of Leishmania spp. genome in peripheral blood of seropositive dogs by real-time polymerase chain reaction (rt-PCR). *Microbial Pathogenesis*, **2019**, 126, 263-268	3.8	8
45	Performance of Leishmania braziliensis enolase protein for the serodiagnosis of canine and human visceral leishmaniosis. *Veterinary Parasitology*, **2017**, 238, 77-81	2.8	7
44	Leishmania infantum amastin protein incorporated in distinct adjuvant systems induces protection against visceral leishmaniasis. *Cytokine*, **2020**, 129, 155031	4	7
43	A chloroquinoline derivate presents effective in vitro and in vivo antileishmanial activity against Leishmania species that cause tegumentary and visceral leishmaniasis. *Parasitology International*, **2019**, 73, 101966	2.1	7
42	A Leishmania infantum hypothetical protein evaluated as a recombinant protein and specific B-cell epitope for the serodiagnosis and prognosis of visceral leishmaniasis. *Acta Tropica*, **2020**, 203, 105318	3.2	7
41	In silico Leishmania proteome mining applied to identify drug target potential to be used to treat against visceral and tegumentary leishmaniasis. *Journal of Molecular Graphics and Modelling*, **2019**, 87, 89-97	2.8	7
40	Synthesis and antileishmanial activity of 1,3-bis(aryloxy)propan-2-amines. *Medicinal Chemistry Research*, **2017**, 26, 1052-1072	2.2	6
39	Synthesis, antileishmanial activity and QSAR studies of 2-chloro- N -arylacetamides. *Brazilian Journal of Pharmaceutical Sciences*, **2017**, 53,	1.8	6
38	Resveratrol analogues present effective antileishmanial activity against promastigotes and amastigotes from distinct Leishmania species by multitarget action in the parasites. *Journal of Pharmacy and Pharmacology*, **2019**, 71, 1854-1863	4.8	6
37	Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans. *Cellular Immunology*, **2018**, 331, 67-77	4.4	6
36	A Computational Approach Using Bioinformatics to Screening Drug Targets for Species. *Evidence-based Complementary and Alternative Medicine*, **2018**, 2018, 6813467	2.3	6

35	In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species. *Acta Tropica*, **2019**, 191, 29-37	3.2	5
34	Diagnostic markers selected by immunoproteomics and phage display applied for the serodiagnosis of canine leishmaniosis. *Research in Veterinary Science*, **2019**, 126, 4-8	2.5	4
33	Leishmania infantum pyridoxal kinase evaluated in a recombinant protein and DNA vaccine to protects against visceral leishmaniasis. *Molecular Immunology*, **2020**, 124, 161-171	4.3	4
32	A new Leishmania hypothetical protein can be used for accurate serodiagnosis of canine and human visceral leishmaniasis and as a potential prognostic marker for human disease. *Experimental Parasitology*, **2020**, 216, 107941	2.1	4
31	An immunoproteomics approach to identify proteins to be applied for the diagnosis of visceral leishmaniasis and human immunodeficiency virus co-infection. *Parasitology*, **2020**, 147, 932-939	2.7	4
30	Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis. *Parasite Immunology*, **2020**, 42, e12784	2.2	4
29	Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis. *Parasitology Research*, **2021** , 120, 321-335	2.4	4
28	Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis. *Experimental Parasitology*, **2021**, 221, 108059	2.1	4
27	Evaluation of Leishmania infantum pyridoxal kinase protein for the diagnosis of human and canine visceral leishmaniasis. *Immunology Letters*, **2020**, 220, 11-20	4.1	3
26	Cross-protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis. *Parasite Immunology*, **2016**, 38, 108-17	2.2	3
25	In vitro and in vivo antileishmanial activity of □acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis. *Parasite*, **2021**, 28, 38	3	3
24	1,3-Bis(aryloxy)propan-2-ols as potential antileishmanial agents. *Chemical Biology and Drug Design*, **2017**, 90, 981-986	2.9	2
23	Evaluation of the protective efficacy of a Leishmania protein associated with distinct adjuvants against visceral leishmaniasis and in vitro immunogenicity in human cells. *Parasitology Research*, **2020**, 119, 2609-2622	2.4	2
22	Biotechnological applications from a Leishmania amastigote-specific hypothetical protein in the canine and human visceral leishmaniasis. *Microbial Pathogenesis*, **2020**, 147, 104283	3.8	2
21	Leishmanicidal activity of ibuprofen and its complexes with Ni(II), Mn(II) and Pd(II). *Inorganic Chemistry Communication*, **2020**, 113, 107756	3.1	2
20	A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis. *Cellular Immunology*, **2020**, 356, 104194	4.4	2
19	Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis. *Medical Microbiology and Immunology*, **2021**, 210, 133-147	4	2
18	Serodiagnosis of canine leishmaniasis using a novel recombinant chimeric protein constructed with distinct B-cell epitopes from antigenic Leishmania infantum proteins. *Veterinary Parasitology*, **2021**, 296, 109513	2.8	2

17	Development of a chimeric protein based on a proteomic approach for the serological diagnosis of human tegumentary leishmaniasis. *Applied Microbiology and Biotechnology*, **2021**, 105, 6805-6817	5.7	2
16	Sensitive and specific serodiagnosis of tegumentary leishmaniasis using a new chimeric protein based on specific B-cell epitopes of Leishmania antigenic proteins. *Microbial Pathogenesis*, **2021**, 162, 105341	3.8	1
15	ChimLeish, a new recombinant chimeric protein evaluated as a diagnostic and prognostic marker for visceral leishmaniasis and human immunodeficiency virus coinfection. *Parasitology Research*, **2021**, 120, 4037-4047	2.4	1
14	Leishmania eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against Leishmania infantum infection. *Microbial Pathogenesis*, **2021**, 151, 104745	3.8	1
13	Potential of recombinant LiHyQ, a novel Leishmania infantum protein, for the diagnosis of canine visceral leishmaniasis and as a diagnostic and prognostic marker for human leishmaniasis and human immunodeficiency virus co-infection: A preliminary study. *Acta Tropica*, **2021**, 224, 106126	3.2	1
12	In Silico Design of Recombinant Chimera T Cell Peptide Epitope Vaccines for Visceral Leishmaniasis.. *Methods in Molecular Biology*, **2022**, 2410, 463-480	1.4	1
11	Preclinical Assessment of the Immunogenicity of Experimental Leishmania Vaccines.. *Methods in Molecular Biology*, **2022**, 2410, 481-502	1.4	1
10	Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary study.. *Experimental Parasitology*, **2021**, 233, 108205	2.1	0
9	Application of Poloxamers for the Development of Drug Delivery System to Treat Leishmaniasis: A Review. *Current Drug Targets*, **2021**, 22, 296-309	3	0
8	Diagnostic application of sensitive and specific phage-exposed epitopes for visceral leishmaniasis and human immunodeficiency virus coinfection.. *Parasitology*, **2021**, 148, 1706-1714	2.7	0
7	Recombinant guanosine-5∀triphosphate (GTP)-binding protein associated with Poloxamer 407-based polymeric micelles protects against Leishmania infantum infection.. *Cytokine*, **2022**, 153, 155865	4	0
6	A recombinant Leishmania amastigote-specific protein, rLiHyG, with adjuvants, protects against infection with Leishmania infantum.. *Acta Tropica*, **2022**, 230, 106412	3.2	0
5	Leishmania LiHyC protein is immunogenic and induces protection against visceral leishmaniasis.. *Parasite Immunology*, **2022**, e12921	2.2	0
4	Evaluation from a B-cell epitope-based chimeric protein for the serodiagnosis of tegumentary and visceral leishmaniasis.. *Microbial Pathogenesis*, **2022**, 167, 105562	3.8	0
3	Mapping linear B-cell epitopes of the Tryparedoxin Peroxidase and its implications in the serological diagnosis of tegumentary leishmaniasis. *Acta Tropica*, **2022**, 106521	3.2	0
2	A simple quinoline salt derivative is active in vitro against Plasmodiumfalciparum asexual blood stages and inhibits the development of cerebral malaria in murine model.. *Chemico-Biological Interactions*, **2022**, 355, 109848	5	
1	Efficacy of the 7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline derivative against infection caused by Leishmania amazonensis. *Revista Da Sociedade Brasileira De Medicina Tropical*, **2020**, 53, e20200091	1.5	